Navigation Links
QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
Date:8/31/2010

SYDNEY and BEDMINSTER, N.J., Aug. 31 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal.  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain.  Featured speakers who will highlight Dual Opioids at this symposium are internationally recognised pain experts, Drs. Nicholson, Pasternak and Webster.

In addition to the symposium, QRxPharma was invited to present three posters on September 2, from 9:30-10:30 with the results from MoxDuo IR comparative trials:

  • "Morphine Equivalent Doses of Dual Opioid Treatment With Morphine Plus Oxycodone Versus Morphine and Oxycodone Monotherapy for Post-Operative Pain: Safety and Analgesic Profiles"
  • "Treatment of Post-Operative Pain With a Dual Opioid Combination of Morphine and Oxycodone: Analgesia and Side Effects"
  • "An Active Controlled Evaluation of the Efficacy and Safety of Dual Opioid Treatment With Morphine Plus Oxycodone for Acute Pain Following Total Knee Arthroplasty"

In the recently completed Phase 3 Combination Rule Study, MoxDuo IR demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components.  The Company is currently completing its final Phase 3 registration trial for MoxDuo IR in patients who have undergone total knee replacement surgery.

When compared to other opioids at equi-analgesic doses, MoxDuo IR reduced the occurrence rate and intensity of moderate to severe nausea, vomiting and dizziness by 50-75% or more (study 021) and demonstrated when such Adverse Events (AEs) do occu
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... Nov. 12 A new treatment for autism appears ... S. Starr, MD, FAACAP, BCIA-EEG. , In ... characteristically common "u" EEG pattern reflecting impaired brain function, ... interaction, communication, speech and bonding. , ...
... MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire / -- ... for Integrative Oncology,s (SIO) Sixth International Conference in ... and safety of complementary and alternative medicine (CAM) ... Director, Hematology/Oncology at Children,s Hospitals and Clinics of ...
Cached Medicine Technology:New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:12/21/2014)... 21, 2014 Serious Buyer, Andrew Hawley ... Jm Morrison and the Doors International Ballroom at the ... also be the only time that Morrison's mother would ... Nov. 25, 1967. According to Hawley, “This would be ... play the Alexandria Roller Rink earlier that year and ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 BambooIndustry.com ... . Recently, the business has announced its bamboo ... buys the best material from certified suppliers, and ... its customers worldwide. In the current promotion, all ... 20% off, when they say they know BambooIndustry.com ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... new study it was found that in case of ... above, their mental abilities are on the decline due ... York City at the 21st Annual Scientific Meeting of ... measured blood pressure and cognitive function in 101 Japanese ...
... signaling pathways in the immune cells that seem to point ... system.// This new research could be important in uncovering for ... entry into the cells. ,The cell culture study ... and the University of Pennsylvania appears in the Proceedings of ...
... American Journal of Respiratory and Critical Care Medicine says that ... in lung capacity equivalent to what usually happens after 12 ... ,An average loss of 372 milliliters was noted, which ... loss is at least 10 times more than the annual ...
... Anti-depressant Prozac’s journey in the brain and its ultimate ... Spring Harbor Laboratory on Long Island. //This finding will ... will have relatively lesser side effects. ,The ... the factors that control how, when, and where new ...
... A new study that has thrown light on allergic reactions ... children who get bitten by insects are in need of ... display any adverse allergic symptoms. ,The study, entitled “Allergic reactions ... junior high school children in Israel” can be found in ...
... the University of California, San Francisco (UCSF) it is possible ... supplements in infants and children are a novel method for ... the Department of General Pediatrics at UCSF Children's Hospital and ... is no specific way by which one can prevent asthma. ...
Cached Medicine News:Health News:As You Age Check Your BP for It Can Affect Your Mental Ability 2Health News:Link Between Immune System And Nervous System 2Health News:Ultimate Destination of anti-depressant, Prozac 2Health News:Insect Bites Among Children Do Not Warrant Medical Attention In Most Cases 2Health News:Introduction of Microbial Organisms: A Possible Treatment for Asthma 2
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
Measure SpO2 and tcpCO2 with a single sensor....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: